A case report of probable cortical basal ganglia degeneration misdiagnosed as Parkinson’s disease

jing li¹, miao yu², and mengru lu³

¹Guangxi Medical University Cancer Hospital  
²Weifang People’s Hospital  
³The Second Affiliated Hospital of Guangxi Medical University

May 23, 2024

Introduction:
Cortical basal ganglia degeneration (CBD) is currently considered to be a rare neurodegenerative disease characterized by pathological tau deposition, neuronal loss, ballooning, and glial degeneration in atrophic cerebral cortex and subcortical regions (including the substantia nigra and striatum) (1). On CBD magnetic resonance, the majority showed asymmetric cortical atrophy in the frontal, temporal, and parietal lobes of the brain. Typical MRI findings are asymmetric cortical atrophy in the premotor area, supplementary motor area and posterior cingulate gyrus, and middle frontal lobe (2). In this paper, we report a case of CBD misdiagnosed as Parkinson’s disease to summarize its clinical manifestations and imaging features, and have some experience in encountering such diseases in the future.

Case Report
The patient, a 75-year-old male, was admitted due to "stiffness of the left upper limb and slow movement for four years". Four years ago, the patient complained of stiff left shoelaces and slow movement without falling. The symptoms aggravated gradually and flexibility decreased steadily. In November 2020, the patient visited a local hospital and was diagnosed with "Parkinson’s disease". When the patient took Madopar, he felt a certain but subtle effect. Since then, the patient had been undergoing treatment for "Parkinson’s disease". In the recent one year, he experienced a muscle tension disorder of left upper limb. However, since the onset of the disease, the patient had no hyposmia, no dream-enacting behavior, conscious memory loss, no orthostatic dizziness, no hallucinations, auditory hallucinations or other phenomena, no urinary incontinence, fecal constipation, normal sleep, and no significant weight loss. The patient had a 5-year history of hypertension, with a maximum blood pressure of 180/105 mmHg. He took Amlodipine Tablets 5 mg on a regular basis and had fair blood pressure control. Additional medical history was unremarkable. The patient denied having similar medical history in the family. Nervous system: Normal vital signs, NEWS1 score, clear mind, answering the questions correctly, normal upper and lower vision, cranial nerve examination (-), soft neck, no resistance, normal muscle strength and increased muscle tension of the left upper limb, normal muscle tension of the left lower limb, left limb muscle tension disorder, left hand apraxia, normal muscle tension and muscle strength of the right side, less stable left finger-nose test, clumsy rapid rotation movement of the left side, normal heel-shin test, left cortical sensory disturbance, left limb, pathological signs (-). Anti-glomerular basal ganglia antibody (-), T-Sport (-), ENA antibody spectrum (-), double-stranded DNA quantification, glycosylated hemoglobin was normal, urination, HIV, RPR, TPPA, vitamin B12, folic acid, hepatitis virus screening (-), anticardiolipin antibody (-), coagulation, euthyroidism, infectious disease screening, tumor markers, calcitonin and antimuclear antibodies, blood routine, liver and kidney function, electrolytes, myocardial enzyme spectrum, ceruloplasmin were all normal, and blood lipid panel was not significantly abnormal. No Tau protein-related gene mutation. Magnetic resonance imaging: (Figure1A-E). Residual urine 26 ml, standing...
decubitus pulse pressure difference < 10 mmHg, MMSE 24 points (university education level), MoCA 20 points, UPDRS III part 36 points, no anxiety and depression state. The PET-CT results revealed that the patient had FDG hypometabolism in the right precentral gyrus and hypometabolism in the left cerebellum. There was abnormal deposition of tau in striatum, thalamus, midbrain, and pons, and parietal cortex. He also had decreased DaT (dopamine transporter) in the right anterior and posterior putame.

Diagnosis: Cortical basal ganglia degeneration (CBD), the diagnosis of CBD disease, is generally considered the gold standard for pathological diagnosis, but because cases cannot be taken owing to limited conditions, it is deemed to be probable CBD according to the current diagnostic criteria for CBD in China (3).

Treatment and follow-up: After admission, the patient was given Madopar 0.25g po tid, Vitamin B6 10 mg po tid, and Selegiline 1 mg po at noon of 1 morning. Madopar was noted to be 1.5 hours apart from the diet. During follow-up after 1 month, the symptoms were slightly improved than before.

Discussion
Clinical presentation of CBD is characterized by different combinations of motor symptoms, some of which are associated with higher cortical lesions. It is mainly characterized by parkinson-like symptoms combined with dystonia and myoclonus. Levodopa is ineffective in most patients and, in very few cases, mild to moderate remission may occur after levodopa therapy. However, remission occurs for a short time, and the after-effect is poor. Higher cortical symptoms are mainly changes such as conceptual apraxia, aphasia, cortical sensory disturbances, cognitive dysfunction, visuospatial disturbances, foreign limbs, and frozen gait (74). Therefore, it is easily misdiagnosed as Parkinson’s disease in the early stages. Positron emission tomography (PET) examination showed that glucose metabolism (FDG) was low in the frontal lobe (including superior frontal gyrus, middle frontal gyrus, inferior frontal gyrus, and precentral gyrus), parietal lobe (including superior parietal lobule, parietal lobule, angular gyrus, supramarginal gyrus, and precuneus), occipital lobe (middle occipital gyrus), temporal lobe (including middle temporal gyrus, inferior temporal gyrus, transverse temporal gyrus, and shuttle gyrus), insula, and thalamus of the severely affected limb in CBD patients. On the contrary, glucose metabolism (FDG) was relatively high in the ipsilateral precentral gyrus, postcentral gyrus, hippocampus, insula, putamen, cerebellum, paracentral lobule, and pons. Dopamine transporter (DAT) imaging can reveal reduced DaT in the asymmetric cortex and basal ganglia of CBD patients (85). PET-tau imaging can detect Tau deposition in the cortex and basal ganglia of CBD patients (96). The PET-CT in our patient revealed FDG hypometabolism in the right precentral gyrus and the left cerebellum, which is in line with the aforementioned reports. Furthermore, the abnormal tau deposition in striatum, thalamus, midbrain, and pons, as well as in the parietal cortex was consistent with previous findings. In addition, the reported DaT metabolism in this case was very characteristic, with DaT decreased in the anterior and posterior parts of the right putamen. Therefore, a probable CBD diagnosis was considered in this case. There is no effective treatment, and the average survival years of CBD has been reported to be 5–7 years (107), based primarily on symptomatic treatment. However, certain CBD patients can respond effectively to levodopa, and those who do not respond to levodopa can be treated with an increased dose of compound levodopa of 1.0 g/d, which can be discontinued after two months if no significant improvement is noted (48). Botulinum toxin administered intramuscularly alleviates muscle tension disorders (59). Recently, it has been shown that repetitive transcranial magnetic stimulation may improve the quality of life of CBD patients (10).

Summary
In clinical work, if motor disorders develop in unilateral limbs and last for more than three years, patients with severe limb asymmetry must be examined for cortex function, such as the presence or absence of apraxia, foreign limbs, and cortical compound sensory disorders. Patients with CBD are easily misdiagnosed as having PD in the early stages. Therefore, more meticulous inquiry and differential diagnosis involving the combined CBD and PD diagnostic criteria are required. If conditions permit, PET-CT is a feasible option for further differentiation.

Availability of data and materials
The datasets used during the present study are available from the corresponding author on reasonable request.

**Authors’ contributions**

JL and YU designed the study and wrote the manuscript. MRL contributed to the manuscript revision. JL and YU contributed to the collection of clinical information.

**Ethics approval**

The Guangxi Medical University Review Board provided ethical approval for this study.

**Patient consent for publication**

The written consent to publish was obtained from the patient.

**Declaration of interest’s statement**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Additional information**

No additional information is available for this paper.

**References**


**Figure captions**
Figure 1A-E shows that the right brain atrophy is more significant than the left.

Availability of data and materials